Further to the intimation dated February 19, 2018 regarding US Securities Class Action Lawsuit, Dr. Reddys Laboratories has informed that on March 21, 2019 the United States District Court for the District of New Jersey issued its decision (dated March 20, 2019) granting in part and denying in part its Motion to Dismiss. The Court has dismissed Plaintiff's claims with respect to 17 out of the 22 alleged misstatements. As intimated earlier, the Company believes that the remaining alleged claims of misstatements are without merit and intends to vigorously defend itself against them.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: